Evidence map›Paper›PMID 36754401›Full record

ArticleInternal medicine (Tokyo, Japan)2023

COVID-19 Pneumonia Followed by Anti-signal Recognition Particle Antibody-positive Fibrosing Interstitial Lung Disease.

Tomoya Tateishi, Sho Shimada, Takashi Yamana, Yuki Iijima, Rie Sakakibara, Takahiro Mitsumura, Sho Shibata, Takayuki Honda, Tsuyoshi Shirai, Tsukasa Okamoto and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Tomoya TateishiDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Sho ShimadaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Takashi YamanaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Yuki IijimaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Rie SakakibaraDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Takahiro MitsumuraDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Sho ShibataDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Takayuki HondaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Tsuyoshi ShiraiDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Tsukasa OkamotoDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Meiyo TamaokaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Tsuneo SasaiRheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Japan.
Yasunari MiyazakiDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.
Tokyo Medical and Dental University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is frequently accompanied by various sequelae. Interstitial lung diseases (ILDs) are observed in COVID-19 pneumonia patients after recovery, probably due to persistent inflammation in the lungs. We herein report a case of ILD with anti-signal recognition particle antibodies following severe COVID-19 pneumonia. The patient was diagnosed with ILD three months after COVID-19 pneumonia. Although the exact mechanism is unknown, the autoantibody-induced immune response might have been the pulmonary fibrosis trigger in this patient.

Indexed as

COVID-19Lung Diseases, InterstitialFibrosisHumansLungSARS-CoV-2Signal Recognition ParticleSignal Recognition Particleanti-SRP antibodyCOVID-19interstitial lung diseasepulmonary fibrosis

Identifiers

PMID36754401
PMCPMC10208788
OpenAlexW4319336832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.